LOGO
LOGO

TOI Hits New High - Revenue Projected To Grow 17% To 22% In 2025, Profitable By 2026

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

Shares of The Oncology Institute Inc. (TOI) touched a new 52-week high of $3.76 yesterday, driven by renewed investor confidence and growing market enthusiasm surrounding the company's performance and outlook.

This U.S.-based, community-focused oncology care provider operates 67 clinics across California, Florida, Arizona, Oregon, and Nevada. It offers comprehensive cancer treatment services, including chemotherapy, immunotherapy, oncolytics, and radiation oncology. TOI supports patients through coordinated case management, drug formulary oversight, and fully delegated networks of care providers. It also operates a specialty pharmacy that dispenses oral and self-injectable medications both in-office and by mail. Beyond patient care, TOI plays an active role in advancing clinical research in oncology, hematology, and supportive therapies and devices.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Sep 07 – Sep 11, 2026

September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.

RELATED NEWS